Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LIMD2 siRNA
- Development stage
- Preclinical
- Lead developer
- The Wistar Institute
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
LIMD2 siRNA is a small interfering RNA designed to silence the expression of the LIM domain-containing protein 2 (LIMD2). LIMD2 is a member of the LIM-only family of proteins and has been identified as a biomarker and functional effector of metastasis in various aggressive tumor types, including papillary thyroid carcinoma, melanoma, breast, and bladder cancer. By utilizing the RNA interference (RNAi) pathway, LIMD2 siRNA targets LIMD2 mRNA for degradation, thereby reducing LIMD2 protein levels. This knockdown has been shown to decrease the migratory and colony-forming abilities of malignant cells and induce morphological changes, suggesting that LIMD2 is a critical regulator of the metastatic phenotype. Consequently, LIMD2 siRNA represents a potential therapeutic strategy to inhibit tumor progression and improve the efficacy of conventional cancer treatments.
- Other names
- siRNA targeting LIMD2LIMD2-specific siRNALIMD-2-specific siRNALIMD 2-specific siRNA
02
Targets
LIMD2 (LIM domain-containing protein 2)Innate immune RNA sensors
Beyond the preview
Go deeper on LIMD2 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LIMD2 siRNA.